{"id":464623,"date":"2021-03-24T16:33:20","date_gmt":"2021-03-24T20:33:20","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=464623"},"modified":"2021-03-24T16:33:20","modified_gmt":"2021-03-24T20:33:20","slug":"mustang-bio-reports-full-year-2020-financial-results-and-recent-corporate-highlights","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-reports-full-year-2020-financial-results-and-recent-corporate-highlights\/","title":{"rendered":"Mustang Bio Reports Full-Year 2020 Financial Results and Recent Corporate Highlights"},"content":{"rendered":"
\n

NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (\u201cMustang\u201d) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today\u2019s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the full year ended December 31, 2020.<\/p>\n

Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, \u201cWe are excited by the progress across our cell and gene therapy programs in 2020. Notably, MB-106 (CD20-targeted, autologous CAR T cell therapy) data were presented at the 62nd American Society of Hematology (\u201cASH\u201d) Annual Meeting which showed a favorable safety profile and clinical activity, with an 89% overall response rate and 44% complete response rate in patients with relapsed or refractory B-cell non-Hodgkin lymphomas who were treated with the modified cell manufacturing process. In August, we initiated an open-label, multicenter Phase 1\/2 clinical trial to evaluate the safety and efficacy of MB-102 (CD123-targeted CAR T cell therapy) in patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm (\u201cBPDCN\u201d). In October, initial Phase 1 data on MB-105, a PSCA-targeted CAR T cell therapy administered systemically to patients with PSCA-positive metastatic castration-resistant prostate cancer (\u201cmCRPC\u201d), demonstrated a 94% reduction in prostate-specific antigen, near complete reduction of measurable soft tissue metastasis by computerized tomography, and improvement in bone metastases by magnetic resonance imaging in a 73-year-old male patient with PSCA-positive mCRPC who failed eight prior therapies.\u201d<\/p>\n

Dr. Litchman continued, \u201cIn 2021, we anticipate multiple potential data disclosures from our collaborators\u2019 clinical trials, and we plan to have four open Mustang Investigational New Drug (\u201cIND\u201d) applications. We look forward to advancing our lentiviral gene therapy clinical program for the treatment of X-linked severe combined immunodeficiency (\u201cXSCID\u201d), also known as bubble boy disease. In the second quarter, we plan to begin enrollment on our pivotal multicenter Phase 2 trial of MB-107 in newly diagnosed infants with XSCID who are under the age of two and submit an IND application for a pivotal multicenter Phase 2 trial of MB-207 for the treatment of patients with XSCID who were previously treated with hematopoietic stem cell transplant (\u201cHSCT\u201d) and for whom re-treatment is indicated. With a robust pipeline of therapies addressing highly challenging diseases, world-class R&D collaborators, a state-of-the-art cell processing facility and an experienced team, I believe we are very well positioned to continue building a fully integrated cell and gene therapy company.\u201d<\/p>\n

\n
\n Financial Results:<\/u>
\n <\/strong>\n <\/p>\n